, /PRNewswire/ -- Eli Lilly and Company (NYSE: ) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with G12C-mutant advanced solid tumors and in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with G12C-mutant advanced non-small cell lung cancer (NSCLC). Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. These data will be shared in oral presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
"Despite recent advances, there remains a significant unmet need for patients with G12C-mutant cancers," said , M.D., Ph.
D., Associate Professor of Medicine, Medical Center Hillman Cancer Center. "These data show efficacy with olomorasib across tumor types and, importantly, tolerability that suggests it can be combined with immunotherapy, the backbone of first-line treatment for -mutant NSCLC.
In NSCLC, it is also exciting to see promising activity in patients previously treated with a KRAS G12C inhibitor as well as central nervous system (CNS) activity, consistent with the improved potency of this second generation KRAS G12C inhibitor. Collectively, these data point to a promising emerging profile for olomorasib, particularly in NSCLC where new options are needed to improve outcomes for patients." "As a second generation KRAS G12C inhibitor, olomorasib was specifically designed to offer a di.
